Joincare Pharmaceutical Group IndustryLtd Valuation

Is JCARE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of JCARE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: JCARE ($8) is trading below our estimate of fair value ($33.92)

Significantly Below Fair Value: JCARE is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for JCARE?

Key metric: As JCARE is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for JCARE. This is calculated by dividing JCARE's market cap by their current earnings.
What is JCARE's PE Ratio?
PE Ratio	14.6x
Earnings	CN¥1.47b
Market Cap	CN¥21.52b

JCARE key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.3x
Enterprise Value/EBITDA	4.8x
PEG Ratio	1.2x

Price to Earnings Ratio vs Peers

How does JCARE's PE Ratio compare to its peers?

The above table shows the PE ratio for JCARE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	22.9x
DESN Dottikon ES Holding	39.8x	n/a	CHF 3.2b
COPN Cosmo Pharmaceuticals	15.5x	17.2%	CHF 1.0b
NOVN Novartis	17.5x	7.0%	CHF 182.4b
ROG Roche Holding	19x	11.1%	CHF 203.6b
JCARE Joincare Pharmaceutical Group IndustryLtd	14.6x	11.8%	US$21.5b

Price-To-Earnings vs Peers: JCARE is good value based on its Price-To-Earnings Ratio (14.6x) compared to the peer average (22.9x).

Price to Earnings Ratio vs Industry

How does JCARE's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 Company	Price / Earnings	Estimated Growth	Market Cap

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: JCARE is good value based on its Price-To-Earnings Ratio (14.6x) compared to the European Pharmaceuticals industry average (20.7x).

Price to Earnings Ratio vs Fair Ratio

What is JCARE's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

JCARE PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	14.6x
Fair PE Ratio	18.4x

Price-To-Earnings vs Fair Ratio: JCARE is good value based on its Price-To-Earnings Ratio (14.6x) compared to the estimated Fair Price-To-Earnings Ratio (18.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Roche Holding

CHF 203.6b

Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania.

ROG

CHF 253.50

-4.5%

6.9%

Gerresheimer

€2.5b

Manufactures and sells medicine packaging, drug delivery devices, and solutions in Germany and internationally.

GXI

€75.60

Bristol-Myers Squibb

US$100.3b

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.

BMY

US$54.24